Title(s):
Assistant Professor of Oncology
Appointment Phone:
410-955-8964
Primary Location:
Johns Hopkins Sidney Kimmel Comprehensive Cancer Center
Expertise:
Brain Cancer, Brain Tumors, General Internal Medicine, Medical Oncology, Neuro-Oncology
Education and Experience
Training
- Freie Universitat Berlin (Berlin )/ (2003)
Residencies
- Johns Hopkins Bayview Medical Center (Baltimore MD)/ Internal Medicine (2007)
Fellowships
- The Johns Hopkins Hospital (Baltimore MD)/ Oncology (2010)
Certifications
- Oncology, American Board of Internal Medicine (2009)
- Internal Medicine, American Board of Internal Medicine (2007)
Locations
Johns Hopkins Sidney Kimmel Comprehensive Cancer Center
401 N. Broadway
Baltimore, MD 21231
Phone: 410-955-8964
Appointment Phone: 410-955-8964
Location Map
Department / Division
- Oncology
Centers/Institutes
Centers / Institutes
- Sidney Kimmel Comprehensive Cancer Center
Bio
Biography
Holdhoff trained as a clinical translational investigator for the last three years under Stuart Grossman, M.D., Luis Diaz, M.D., and Bert Vogelstein, M.D. He will continue his translational brain tumor research in the Kimmel Cancer Centers Brain Cancer program and the Ludwig Center for Cancer Genetics and Therapeutics. Holdhoffs primary focus will be the development of blood-based tumor markers for patients with malignant gliomas and primary CNS lymphomas and novel translational clinical trials.
Holdhoff received his medical degree in 2003 from Freie Universitt Berlin. He received his doctorate degree (Ph. D.) from Charit University Medicine Berlin magna cum laude. He completed his internal medicine training at Johns Hopkins Bayview Medical Center and he became board-certified in internal medicine in 2007. Holdhoff completed his medical oncology and neuro-oncology training at Johns Hopkins at the end of June 2010 and has already received ABIM board certification in Medical Oncology. He was given the 2010 ASCO Young Investigator Award for his proposal on the development of a blood-based biomarker for malignant gliomas.
Holdhoffs position will actively link the Brain Cancer program and the Ludwig Center, thereby promoting a translational research exchange between the two groups.
Holdhoff received his medical degree in 2003 from Freie Universitt Berlin. He received his doctorate degree (Ph. D.) from Charit University Medicine Berlin magna cum laude. He completed his internal medicine training at Johns Hopkins Bayview Medical Center and he became board-certified in internal medicine in 2007. Holdhoff completed his medical oncology and neuro-oncology training at Johns Hopkins at the end of June 2010 and has already received ABIM board certification in Medical Oncology. He was given the 2010 ASCO Young Investigator Award for his proposal on the development of a blood-based biomarker for malignant gliomas.
Holdhoffs position will actively link the Brain Cancer program and the Ludwig Center, thereby promoting a translational research exchange between the two groups.
Expertise
- Brain Cancer
- Brain Tumors
- General Internal Medicine
- Medical Oncology
- Neuro-Oncology
Research
Research and Publications
Dr. Holdhoff's research is focused on translational research projects and clinical trials in neuro-oncology. As a member of the Brain Cancer Program and the Ludwig Center for Cancer Genetics and Therapeutics at Johns Hopkins, he heads a working group for the development of blood-based biomarkers in malignant gliomas. Dr. Holdhoff graduated from medical school at Freie Universitt Berlin and he received his doctorate degree (German PhD equivalent) at Charit University Medicine Berlin. After internal medicine training at Johns Hopkins Bayview Medical Center he completed his medical oncology fellowship and subspecialty training in neuro-oncology at the Sidney Kimmel Comprehensive Cancer Center. Dr. Holdhoff is board certified in internal medicine and medical oncology and he has a clinic for patients with primary brain tumors, CNS lymphomas and other malignancies of the central nervous system.
Journal Citations
Holdhoff M, Supko JG, Gallia GL, Hann CL, Bonekamp D, Ye X, Cao B, Olivi A, Grossman SA. Intratumoral concentrations of imatinib after oral administration in patients with glioblastoma multiforme. J. Neurooncol 2010; 97: 241-5 (Epub ahead of print Sept 19, 2009).
Holdhoff M, Schmidt K, Donehower R, Diaz LA, Jr. Analysis of Circulating Tumor DNA to Confirm Somatic KRAS Mutations. J Natl Cancer Inst 2009; 101: 1284-5.
Holdhoff M, Parsons DW, Diaz LA, Jr. Mutations of IDH1 and IDH2 are not detected in brain metastases of colorectal cancer. J Neurooncol 2009; 94: 297 (Epub ahead of print April 7).
Holdhoff M, Wung PK, Petronis JD, Couzi R. Persistent positron emission tomography-positive liver lesions after successful chemotherapy in mediastinal seminoma. J Clin Oncol. 2007; 25: 2482-4.
Holdhoff M, Kreuzer KA, Appelt C, Scholz R, Na IK, Hildebrandt B, Riess H, Jordan A, Schmidt CA, Van Etten RA, Drken B, le Coutre P. Radiosensitization of a human glioblastoma cell line by imatinib mesylate through inhibition of platelet-derived growth factor receptor. Blood Cells Mol Dis 2005; 34: 181-185.
le Coutre P, Kreuzer KA, Na IK, Schwarz M, Lupberger J, Holdhoff M, Baskaynak G, Gschaidmeier H, Platzbecker U, Ehninger G, Prejzner W, Huhn D, Schmidt CA: Imatinib in Philadelphia chromosome positive chronic phase CML patients: molecular and cytogenetic response rates and prediction of clinical outcome. Am J Hematol 2003; 73: 249-255.
le Coutre P, Kreuzer KA, Na IK, Lupberger J, Holdhoff M, Appelt, C, Schwarz M, Mller C, Gambacorti-Passerini C, Platzbecker U, Bonnet R, Ehninger G, Schmidt CA: Determination of alpha-1 acid glycoprotein in patients with Ph+ chronic myeloid leukaemia during the first 13 weeks of therapy with STI571. Blood Cells Mol Dis 2002; 28: 75-85.
Journal Citations
Holdhoff M, Supko JG, Gallia GL, Hann CL, Bonekamp D, Ye X, Cao B, Olivi A, Grossman SA. Intratumoral concentrations of imatinib after oral administration in patients with glioblastoma multiforme. J. Neurooncol 2010; 97: 241-5 (Epub ahead of print Sept 19, 2009).
Holdhoff M, Schmidt K, Donehower R, Diaz LA, Jr. Analysis of Circulating Tumor DNA to Confirm Somatic KRAS Mutations. J Natl Cancer Inst 2009; 101: 1284-5.
Holdhoff M, Parsons DW, Diaz LA, Jr. Mutations of IDH1 and IDH2 are not detected in brain metastases of colorectal cancer. J Neurooncol 2009; 94: 297 (Epub ahead of print April 7).
Holdhoff M, Wung PK, Petronis JD, Couzi R. Persistent positron emission tomography-positive liver lesions after successful chemotherapy in mediastinal seminoma. J Clin Oncol. 2007; 25: 2482-4.
Holdhoff M, Kreuzer KA, Appelt C, Scholz R, Na IK, Hildebrandt B, Riess H, Jordan A, Schmidt CA, Van Etten RA, Drken B, le Coutre P. Radiosensitization of a human glioblastoma cell line by imatinib mesylate through inhibition of platelet-derived growth factor receptor. Blood Cells Mol Dis 2005; 34: 181-185.
le Coutre P, Kreuzer KA, Na IK, Schwarz M, Lupberger J, Holdhoff M, Baskaynak G, Gschaidmeier H, Platzbecker U, Ehninger G, Prejzner W, Huhn D, Schmidt CA: Imatinib in Philadelphia chromosome positive chronic phase CML patients: molecular and cytogenetic response rates and prediction of clinical outcome. Am J Hematol 2003; 73: 249-255.
le Coutre P, Kreuzer KA, Na IK, Lupberger J, Holdhoff M, Appelt, C, Schwarz M, Mller C, Gambacorti-Passerini C, Platzbecker U, Bonnet R, Ehninger G, Schmidt CA: Determination of alpha-1 acid glycoprotein in patients with Ph+ chronic myeloid leukaemia during the first 13 weeks of therapy with STI571. Blood Cells Mol Dis 2002; 28: 75-85.
Research Interests
- Clinical Trials (therapeutic and diagnostic)
- Brain Tumors
- Translational Research in Neuro-Oncology
Facebook
Twitter
Sharecare
Blogs
YouTube
RSS
Podcasts